Rheumatoid Arthritis Drugs Market by Drug Class (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others), Route of Administration (Oral and Parenteral), and Sales Channel (Prescription-based Drugs, and Over-the-counter Drugs): Global Opportunity Analysis and Industry Forecast, 2020–2027
- ALL4162494
- 219 Pages
- October 2020
- Pharmaceuticals
Rheumatoid arthritis is an autoimmune disease that majorly affects joints along with articular tissues and extra-articular organs. It is considered as a systemic disease, as it affects the cardiac and respiratory system. In addition, this medical condition is often progressive, and results in stiffness, pain, redness, and swelling of joints. Moreover, as no permanent cure is available for rheumatoid arthritis, the aim of the treatment is to reduce pain, prevent bone deformity, decrease inflammation, and improve a person’s overall body function. This is achieved through disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs. However, early diagnosis and treatment are the key for better management of the rheumatoid arthritis.
Alarming rise in incidence of rheumatoid arthritis, increase in demand for DMARDs, and surge in geriatric population across the globe are the key factors that fuel the growth of the global rheumatoid arthritis drugs market. In addition, rise in patient awareness toward availability of various treatments for rheumatoid arthritis, increase in focus of pharmaceutical companies to tap the rare & specialty diseases, and rise in R&D activities and product innovations notably contribute toward the growth of the global market. Moreover, recent advancements in biosimilars, which may be used to treat rheumatoid arthritis and rise in approvals of the same by regulatory authorities drive the growth of the market. However, side effects associated with the medication and high costs of biological DMARD therapies are expected to hinder the growth of the market, globally.
The global rheumatoid arthritis drugs market is segmented into drug class, route of administration, sales channel, and region. Depending on drug class, the market is categorized into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. By route of administration, it is segregated into oral and parenteral. On the basis of sales channel, it is fragmented into prescription-based drugs and over-the-counter drugs. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of four regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Class
• Disease-modifying Anti-Rheumatic Drugs (DMARDs)
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Uric Acid Drugs
• Others
By Route of Administration
• Oral
• Parenteral
By Sales Channel
• Prescription-based Drugs
• Over-the-counter Drugs
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• UCB S.A
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Biogen Inc
• Takeda Pharmaceutical Company
• Swedish Orphan Biovitrum AB (SOBI)
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective44
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Top player positioning, 2019
3.4.Porter’s five force analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in geriatric population across the globe
3.5.1.2.Increase in healthcare expenditure worldwide
3.5.1.3.Rise in prevalence of rheumatoid arthritis across the globe
3.5.2.Restraint
3.5.2.1.Lack of access to treatment of rheumatoid arthritis in underdeveloped countries
3.5.3.Opportunity
3.5.3.1.High growth potential in emerging markets
3.5.4.Impact analysis
3.6.Covid-19 impact analysis on rheumatoid arthritis drugs market
CHAPTER 4:RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.Disease-modifying anti-rheumatic drugs
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Nonsteroidal anti-inflammatory drugs
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Corticosteroids
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Uric acid drugs
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Others
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
CHAPTER 5:RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Oral
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Parenteral
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
CHAPTER 6:RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Prescription-based drugs
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Over-the-counter drugs
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7:RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. rheumatoid arthritis drugs market, by drug class
7.2.2.1.2.U.S. rheumatoid arthritis drugs market, by route of administration
7.2.2.1.3.U.S. rheumatoid arthritis drugs market, by sales channel
7.2.2.2.Canada
7.2.2.2.1.Canada rheumatoid arthritis drugs market, by drug class
7.2.2.2.2.Canada rheumatoid arthritis drugs market, by route of administration
7.2.2.2.3.Canada rheumatoid arthritis drugs market, by sales channel
7.2.2.3.Mexico
7.2.2.3.1.Mexico rheumatoid arthritis drugs market, by drug class
7.2.2.3.2.Mexico rheumatoid arthritis drugs market, by route of administration
7.2.2.3.3.Mexico rheumatoid arthritis drugs market, by sales channel
7.2.3.North America market size and forecast, by drug class
7.2.4.North America market size and forecast, by route of administration
7.2.5.North America market size and forecast, by sales channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany rheumatoid arthritis drugs market, by drug class
7.3.2.1.2.Germany rheumatoid arthritis drugs market, by route of administration
7.3.2.1.3.Germany rheumatoid arthritis drugs market, by sales channel
7.3.2.2.France
7.3.2.2.1.France rheumatoid arthritis drugs market, by drug class
7.3.2.2.2.France rheumatoid arthritis drugs market, by route of administration
7.3.2.2.3.France rheumatoid arthritis drugs market, by sales channel
7.3.2.3.UK
7.3.2.3.1.UK rheumatoid arthritis drugs market, by drug class
7.3.2.3.2.UK rheumatoid arthritis drugs market, by route of administration
7.3.2.3.3.UK rheumatoid arthritis drugs market, by sales channel
7.3.2.4.Italy
7.3.2.4.1.Italy rheumatoid arthritis drugs market, by drug class
7.3.2.4.2.Italy rheumatoid arthritis drugs market, by route of administration
7.3.2.4.3.Italy rheumatoid arthritis drugs market, by sales channel
7.3.2.5.Spain
7.3.2.5.1.Spain rheumatoid arthritis drugs market, by drug class
7.3.2.5.2.Spain rheumatoid arthritis drugs market, by route of administration
7.3.2.5.3.Spain rheumatoid arthritis drugs market, by sales channel
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe rheumatoid arthritis drugs market, by drug class
7.3.2.6.2.Rest of Europe rheumatoid arthritis drugs market, by route of administration
7.3.2.6.3.Rest of Europe rheumatoid arthritis drugs market, by sales channel
7.3.3.Europe market size and forecast, by drug class
7.3.4.Europe market size and forecast, by route of administration
7.3.5.Europe market size and forecast, by sales channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan rheumatoid arthritis drugs market, by drug class
7.4.2.1.2.Japan rheumatoid arthritis drugs market, by route of administration
7.4.2.1.3.Japan rheumatoid arthritis drugs market, by sales channel
7.4.2.2.China
7.4.2.2.1.China rheumatoid arthritis drugs market, by drug class
7.4.2.2.2.China rheumatoid arthritis drugs market, by route of administration
7.4.2.2.3.China rheumatoid arthritis drugs market, by sales channel
7.4.2.3.Australia
7.4.2.3.1.Australia rheumatoid arthritis drugs market, by drug class
7.4.2.3.2.Australia rheumatoid arthritis drugs market, by route of administration
7.4.2.3.3.Australia rheumatoid arthritis drugs market, by sales channel
7.4.2.4.India
7.4.2.4.1.India rheumatoid arthritis drugs market, by drug class
7.4.2.4.2.India rheumatoid arthritis drugs market, by route of administration
7.4.2.4.3.India rheumatoid arthritis drugs market, by sales channel
7.4.2.5.South Korea
7.4.2.5.1.South Korea rheumatoid arthritis drugs market, by drug class
7.4.2.5.2.South Korea rheumatoid arthritis drugs market, by route of administration
7.4.2.5.3.South Korea rheumatoid arthritis drugs market, by sales channel
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific rheumatoid arthritis drugs market, by drug class
7.4.2.6.2.Rest of Asia-Pacific rheumatoid arthritis drugs market, by route of administration
7.4.2.6.3.Rest of Asia-Pacific rheumatoid arthritis drugs market, by sales channel
7.4.3.Asia-Pacific market size and forecast, by drug class
7.4.4.Asia-Pacific market size and forecast, by route of administration
7.4.5.Asia-Pacific market size and forecast, by sales channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil
7.5.2.1.1.Brazil rheumatoid arthritis drugs market, by drug class161
7.5.2.1.2.Brazil rheumatoid arthritis drugs market, by route of administration
7.5.2.1.3.Brazil rheumatoid arthritis drugs market, by sales channel
7.5.2.2.Saudi Arabia
7.5.2.2.1.Saudi Arabia rheumatoid arthritis drugs market, by drug class
7.5.2.2.2.Saudi Arabia rheumatoid arthritis drugs market, by route of administration
7.5.2.2.3.Saudi Arabia rheumatoid arthritis drugs market, by sales channel
7.5.2.3.South Africa
7.5.2.3.1.South Africa rheumatoid arthritis drugs market, by drug class
7.5.2.3.2.South Africa rheumatoid arthritis drugs market, by route of administration
7.5.2.3.3.South Africa rheumatoid arthritis drugs market, by sales channel
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA rheumatoid arthritis drugs market, by drug class
7.5.2.4.2.Rest of LAMEA rheumatoid arthritis drugs market, by route of administration
7.5.2.4.3.Rest of LAMEA rheumatoid arthritis drugs market, by sales channel
7.5.3.LAMEA market size and forecast, by drug class
7.5.4.LAMEA market size and forecast, by route of administration
7.5.5.LAMEA market size and forecast, by sales channel
CHAPTER 8:COMPANY PROFILES
8.1.ABBVIE INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.AMGEN INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.3.BRISTOL-MYERS SQUIBB COMPANY
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.ELI LILLY AND COMPANY
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.F. HOFFMANN-LA ROCHE LTD.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.JOHNSON & JOHNSON
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.MERCK & CO., INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.NOVARTIS AG (SANDOZ)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.PFIZER INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.UCB S.A.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
TABLE 01.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 03.NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 04.CORTICOSTEROIDS RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 05.URIC ACID RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.OTHERS RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 08.ORAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 09.PARENTERAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 11.PRESCRIPTION-BASED RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 12.OVER-THE-COUNTER RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 13.RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 14.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 15.U.S. RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 16.U.S. RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 17.U.S. RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 18.CANADA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 19.CANADA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 20.CANADA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 21.MEXICO RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 22.MEXICO RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 23.MEXICO RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 24.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 25.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 26.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 27.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 29.GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 30.GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 31.FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 32.FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 33.FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 34.UK RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 35.UK RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 36.UK RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 37.ITALY RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 38.ITALY RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 39.ITALY RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 40.SPAIN RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 41.SPAIN RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 42.SPAIN RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 43.REST OF EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 44.REST OF EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 45.REST OF EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 46.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 47.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 48.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 49.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 50.JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 51.JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 52.JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 53.CHINA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 54.CHINA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 55.CHINA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 56.AUSTRALIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 57.AUSTRALIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 58.AUSTRALIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 59.INDIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 60.INDIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 61.INDIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 62.SOUTH KOREA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 63.SOUTH KOREA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 64.SOUTH KOREA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 65.REST OF ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 66.REST OF ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 67.REST OF ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 68.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 69.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 70.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 71.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 72.BRAZIL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 73.BRAZIL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 74.BRAZIL RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 75.SAUDI ARABIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 76.SAUDI ARABIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 77.SAUDI ARABIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 78.SOUTH AFRICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 79.SOUTH AFRICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 80.SOUTH AFRICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 81.REST OF LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 82.REST OF LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 83.REST OF LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 84.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 85.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 86.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 87.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 88.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 89.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90.AMGEN: COMPANY SNAPSHOT
TABLE 91.AMGEN: PRODUCT PORTFOLIO
TABLE 92.BMS: COMPANY SNAPSHOT
TABLE 93.BMS: PRODUCT PORTFOLIO
TABLE 94.LILLY: COMPANY SNAPSHOT
TABLE 95.LILLY: PRODUCT PORTFOLIO
TABLE 96.LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.ROCHE: COMPANY SNAPSHOT
TABLE 98.ROCHE: OPERATING SEGMENT
TABLE 99.ROCHE: PRODUCT PORTFOLIO
TABLE 100.J&J: COMPANY SNAPSHOT
TABLE 101.J&J: OPERATING SEGMENTS
TABLE 102.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 103.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 104.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 105.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 106.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107.NOVARTIS: COMPANY SNAPSHOT
TABLE 108.NOVARTIS: OPERATING SEGMENT
TABLE 109.NOVARTIS: PRODUCT PORTFOLIO
TABLE 110.PFIZER: COMPANY SNAPSHOT
TABLE 111.PFIZER: OPERATING SEGMENT
TABLE 112.PFIZER: PRODUCT PORTFOLIO
TABLE 113.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.UCB: COMPANY SNAPSHOT
TABLE 115.UCB: OPERATING SEGMENT
TABLE 116.UCB: PRODUCT PORTFOLIO
TABLE 117.UCB: KEY STRATEGIC MOVES AND DEVELOPMENTS
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
